Table 1

Characteristics of the patients entered in the trial

Total patients entered25
Evaluable patients22a
Median age ± SD, years64 ± 13 (range, 34–76)
Gender (male/female)12/10 (55%/45%)
ECOGb performance score (%)
 03 (13.6%)
 113 (59.1%)
 26 (27.3%)
Diagnoses (%)
 Lung cancer9 (40.5%)
 Pancreas cancer4 (18.0%)
 Cervical cancer2 (9.0%)
 Sarcoma1 (4.5%)
 Rectal cancer1 (4.5%)
 Breast cancer1 (4.5%)
 Hepatocellular carcinoma1 (4.5%)
 Renal cell carcinoma1 (4.5%)
 Chronic lymphocytic leukemia1 (4.5%)
 Neuroendocrine cancer1 (4.5%)
Prior chemotherapy14 (64%)
Prior other therapyc5 (23%)
No prior therapy3 (14%)
  • a Three patients were entered but received no ω-3 capsules because of withdrawal of consent or rapid progression of disease.

  • b ECOG, Eastern Cooperative Oncology Group.

  • c Includes radiation therapy and immunotherapy.